Cetya Therapeutics, Inc. (“Cetya”) was formed in 2012 to commercialize histone deacetylase inhibitors (HDACi) based on largazole analogs, some of which have bifunctional modifications and the potential to target specific cell types or tumors.
These features are unique in the HDACi space and, together with potency and selectivity, differentiate Cetya’s compounds. Cetya holds exclusive license rights to the largazole analog intellectual property created by Dr. Robert M. Williams at Colorado State University. More than 40 largazole analogs have been synthesized, some with best-in-class profiles as HDACi, including:
- Biochemical and cell-based potency
- Upregulation of fetal hemoglobin expression
- In vivo anti-cancer activity
As a drug class, HDACis are effective in treating certain cancers, and thought leaders in epigenetics believe that this class of compounds may have much broader application in treating other conditions such as:
- Chronic inflammation
- Neurological disorders
- Fibrotic diseases
- HIV (by reactivating latent pools of virus to enhance the efficacy of antiretroviral therapy).
All of these indications will be investigated as the preclinical dataset around Cetya’s analogs matures.
Pioneering Research Team
Cetya Therapeutics is uniquely positioned as a company with a modular and modifiable chemistry platform. Our seasoned management team takes pride in having HDACIs with best-in-class potency and isoform-selective drug candidates.